- Home
- SGC vs CLLS Comparison
SGC vs CLLS Comparison
Compare SGC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- CLLS
- Stock Information
- Founded
- SGC 1920
- CLLS 1999
- Country
- SGC United States
- CLLS France
- Employees
- SGC N/A
- CLLS N/A
- Industry
- SGC Apparel
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- CLLS Health Care
- Exchange
- SGC Nasdaq
- CLLS Nasdaq
- Market Cap
- SGC 281.4M
- CLLS 240.2M
- IPO Year
- SGC N/A
- CLLS 2007
- Fundamental
- Price
- SGC $16.42
- CLLS $1.57
- Analyst Decision
- SGC Strong Buy
- CLLS Buy
- Analyst Count
- SGC 2
- CLLS 3
- Target Price
- SGC $22.50
- CLLS $7.00
- AVG Volume (30 Days)
- SGC 46.5K
- CLLS 56.7K
- Earning Date
- SGC 11-06-2024
- CLLS 11-04-2024
- Dividend Yield
- SGC 3.40%
- CLLS N/A
- EPS Growth
- SGC 79.86
- CLLS N/A
- EPS
- SGC 0.82
- CLLS N/A
- Revenue
- SGC $567,509,000.00
- CLLS $36,042,000.00
- Revenue This Year
- SGC $5.21
- CLLS $271.02
- Revenue Next Year
- SGC $4.02
- CLLS $33.48
- P/E Ratio
- SGC $20.08
- CLLS N/A
- Revenue Growth
- SGC 4.19
- CLLS 46.96
- 52 Week Low
- SGC $11.66
- CLLS $1.53
- 52 Week High
- SGC $21.80
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- SGC 43.16
- CLLS 27.91
- Support Level
- SGC $16.51
- CLLS $1.85
- Resistance Level
- SGC $17.40
- CLLS $2.09
- Average True Range (ATR)
- SGC 0.51
- CLLS 0.09
- MACD
- SGC -0.12
- CLLS -0.04
- Stochastic Oscillator
- SGC 0.00
- CLLS 0.00
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.